In vivometal-catalyzed SeCT therapy by a proapoptotic peptide

Peni Ahmadi, Kyohei Muguruma, Tsung Che Chang, Satoru Tamura, Kazuki Tsubokura, Yasuko Egawa, Takehiro Suzuki, Naoshi Dohmae, Yoichi Nakao, Katsunori Tanaka*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Selective cell tagging (SeCT) therapy is a strategy for labeling a targeted cell with certain chemical moietiesviaa catalytic chemical transformation in order to elicit a therapeutic effect. Herein, we report a cancer therapy based on targeted cell surface tagging with proapoptotic peptides (Ac-GGKLFG-X; X = reactive group) that induce apoptosis when attached to the cell surface. Using either Au-catalyzed amidation or Ru-catalyzed alkylation, these proapoptotic peptides showed excellent therapeutic effects bothin vitroandin vivo. In particular, co-treatment with proapoptotic peptide and the carrier-Ru complex significantly and synergistically inhibited tumor growth and prolonged survival rate of tumor-bearing mice after only a single injection. This is the first report of Ru catalyst applicationin vivo, and this approach could be used in SeCT for cancer therapy.

Original languageEnglish
Pages (from-to)12266-12273
Number of pages8
JournalChemical Science
Issue number37
Publication statusPublished - 2021 Oct 7

ASJC Scopus subject areas

  • General Chemistry


Dive into the research topics of 'In vivometal-catalyzed SeCT therapy by a proapoptotic peptide'. Together they form a unique fingerprint.

Cite this